EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - PubMed (original) (raw)
. 2006 May;42(8):1014-30.
doi: 10.1016/j.ejca.2006.01.025. Epub 2006 Mar 30.
Robert Knobler, Rein Willemze, Ketty Peris, Rudolph Stadler, Liliane Laroche, Michel D'Incan, Annamari Ranki, Nicola Pimpinelli, Pablo Ortiz-Romero, Reinhard Dummer, Teresa Estrach, Sean Whittaker
Affiliations
- PMID: 16574401
- DOI: 10.1016/j.ejca.2006.01.025
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome
Franz Trautinger et al. Eur J Cancer. 2006 May.
Abstract
Several reviews and guidelines on the management of mycosis fungoides and Sézary syndrome (MF/SS) have been published; however, treatment strategies for patients with MF/SS vary from institution to institution and no European consensus has yet been established. There are few phase III trials to support treatment decisions for MF/SS and treatment is often determined by institutional experience. In order to summarise the available evidence and review 'best practices' from each national group, the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force met in September 2004 to establish European guidelines for the treatment of MF/SS. This article reviews the treatment regimens selected for inclusion in the guidelines and summarises the clinical data for treatments appropriate for each stage of MF/SS. Guideline recommendations are presented according to the quality of supporting data, as defined by the Oxford Centre for Evidence-Based Medicine. Skin-directed therapies are the most appropriate option for early-stage MF/SS and most patients can look forward to a normal life expectancy. Patients with advanced disease should be encouraged to participate in clinical trials and maintenance of quality of life should be paramount.
Similar articles
- European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke CD, Ortiz-Romero PL, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer MH, Whittaker S, Willemze R, Knobler R. Trautinger F, et al. Eur J Cancer. 2017 May;77:57-74. doi: 10.1016/j.ejca.2017.02.027. Epub 2017 Mar 31. Eur J Cancer. 2017. PMID: 28365528 Review. - Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Jawed SI, et al. J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2. doi: 10.1016/j.jaad.2013.08.033. J Am Acad Dermatol. 2014. PMID: 24438970 Review. - Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, Wilkins B, Fields PA, Dean A, Webb K, Scarisbrick J, Morris S, Whittaker SJ. Agar NS, et al. J Clin Oncol. 2010 Nov 1;28(31):4730-9. doi: 10.1200/JCO.2009.27.7665. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855822 - A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
Thomas BR, Whittaker S. Thomas BR, et al. Skin Therapy Lett. 2012 Dec;17(10):5-9. Skin Therapy Lett. 2012. PMID: 23223768 Review. - Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Olsen EA, et al. J Am Acad Dermatol. 2011 Feb;64(2):352-404. doi: 10.1016/j.jaad.2010.08.037. Epub 2010 Dec 9. J Am Acad Dermatol. 2011. PMID: 21145619 Review.
Cited by
- Novel therapeutic agents for cutaneous T-Cell lymphoma.
Jain S, Zain J, O'Connor O. Jain S, et al. J Hematol Oncol. 2012 May 17;5:24. doi: 10.1186/1756-8722-5-24. J Hematol Oncol. 2012. PMID: 22594538 Free PMC article. Review. - Interventions for mycosis fungoides.
Valipour A, Jäger M, Wu P, Schmitt J, Bunch C, Weberschock T. Valipour A, et al. Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD008946. doi: 10.1002/14651858.CD008946.pub3. Cochrane Database Syst Rev. 2020. PMID: 32632956 Free PMC article. - Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.
Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C. Li JY, et al. Cancer Manag Res. 2012;4:75-89. doi: 10.2147/CMAR.S9660. Epub 2012 Mar 12. Cancer Manag Res. 2012. PMID: 22457602 Free PMC article. - Current and emerging treatment strategies for cutaneous T-cell lymphoma.
Lansigan F, Foss FM. Lansigan F, et al. Drugs. 2010 Feb 12;70(3):273-86. doi: 10.2165/11532190-000000000-00000. Drugs. 2010. PMID: 20166766 Review. - Efficacy and Side Effects of Narrowband-UVB in Early Stage Cutaneous T-Cell Lymphoma in Jordanian Patients.
Abdallat SA, Alqaqaa AS, Obaidat NA, Alnueimi RF. Abdallat SA, et al. ISRN Dermatol. 2014 Feb 19;2014:951821. doi: 10.1155/2014/951821. eCollection 2014. ISRN Dermatol. 2014. PMID: 24701357 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous